HWAM
TLX

Hennion & Walsh Asset Management’s Telix Pharmaceuticals TLX Stock Holding History

Hennion & Walsh Asset Management’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.73M Buy
+150,138
New +$1.53M 0.05% 422

Other funds holding TLX

CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
AP
Aspect Partners Fairfax, Virginia $268M AUM 22.57% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
S
SignatureFD Atlanta, Georgia $7.49B AUM 24.82% 1-Year Est. Return
BWL
Bogart Wealth LLC Mclean, Virginia $2.92B AUM 23.85% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Hennion & Walsh Asset Management's TLX Position: Q2 2026 in Review

Hennion & Walsh Asset Management opened a new position in Telix Pharmaceuticals (TLX) in Q2 2026: 150,138 shares worth $1.73M. The stake represents 0.05% of the portfolio and ranks #422 among its holdings.

9 funds tracked by Wall St. Rank hold TLX as of Q2 2026.

  • Hennion & Walsh Asset Management held 150,138 shares of Telix Pharmaceuticals worth $1.73M as of Q2 2026.
  • Telix Pharmaceuticals was a new Hennion & Walsh Asset Management position in Q2 2026.
  • Telix Pharmaceuticals made up 0.05% of Hennion & Walsh Asset Management's portfolio in Q2 2026, its #422 holding.
  • 9 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q2 2026.

Based on Hennion & Walsh Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.